<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2955">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05532358</url>
  </required_header>
  <id_info>
    <org_study_id>anle138b-P1-03</org_study_id>
    <secondary_id>2022-002467-30</secondary_id>
    <nct_id>NCT05532358</nct_id>
  </id_info>
  <brief_title>A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)</brief_title>
  <official_title>An Open-Label, One-Sequence, Two-Part Drug-Drug Interaction Study in Healthy Volunteers to Assess the CYP1A2 and CYP3A4 Perpetrator Interaction Potential and CYP1A2 Victim Potential of TEV-56286 (anle138b)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MODAG GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aptuit (Verona) Srl, an Evotec Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quotient Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Teva Pharmaceutical Industries, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MODAG GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this healthy volunteers drug-drug interaction study is to assess the CYP1A2&#xD;
      and CYP3A4 perpetrator interaction potential and CYP1A2 victim potential of TEV-56286&#xD;
      (anle138b).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This a 2-part DDI study that will assess the CYP1A2 and CYP3A4 perpetrator interaction&#xD;
      potential of TEV-56286 single dose and multiple dose, using caffeine and midazolam as&#xD;
      substrates and CYP1A2 victim potential of TEV-56286 (anle138b) at steady state induction&#xD;
      using fluvoxamine as inhibitor [1,2].The estimated time from screening until the follow-up&#xD;
      visit is approximately up to 8 weeks for each subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2022</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Drug drug interaction study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oral pharmacokinetics (PK) of caffeine administered without TEV-56286 in healthy volunteers in the fasted state (Part I).</measure>
    <time_frame>Day 1</time_frame>
    <description>PK parameter: Cmax for caffeine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral pharmacokinetics (PK) of caffeine administered without TEV-56286 in healthy volunteers in the fasted state (Part I).</measure>
    <time_frame>Day 1</time_frame>
    <description>PK parameter: AUC(0-inf) for caffeine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral pharmacokinetics (PK) of caffeine administered without TEV-56286 in healthy volunteers in the fasted state (Part I).</measure>
    <time_frame>Day 1</time_frame>
    <description>PK parameter: AUC (0-last) for caffeine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral pharmacokinetics (PK) of midazolam administered without TEV-56286 in healthy volunteers in the fasted state (Part I).</measure>
    <time_frame>Day 1</time_frame>
    <description>PK parameter: Cmax for midazolam.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral pharmacokinetics (PK) of midazolam administered without TEV-56286 in healthy volunteers in the fasted state (Part I).</measure>
    <time_frame>Day 1</time_frame>
    <description>PK parameter: AUC(0-inf) for midazolam.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral pharmacokinetics (PK) of midazolam administered without TEV-56286 in healthy volunteers in the fasted state (Part I).</measure>
    <time_frame>Day 1</time_frame>
    <description>PK parameter: AUC (0-last) for midazolam.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral pharmacokinetics (PK) of caffeine after single co-administration with TEV-56286 in healthy volunteers in the fasted state (Part I).</measure>
    <time_frame>Day 3</time_frame>
    <description>Cmax for caffeine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral pharmacokinetics (PK) of caffeine after single co-administration with TEV-56286 in healthy volunteers in the fasted state (Part I).</measure>
    <time_frame>Day 3</time_frame>
    <description>PK parameter: AUC(0-inf) for caffeine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral pharmacokinetics (PK) of caffeine after single co-administration with TEV-56286 in healthy volunteers in the fasted state (Part I).</measure>
    <time_frame>Day 3</time_frame>
    <description>PK parameter: AUC (0-last) for caffeine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral pharmacokinetics (PK) of midazolam after single co-administration with TEV-56286 in healthy volunteers in the fasted state (Part I).</measure>
    <time_frame>Day 3</time_frame>
    <description>Cmax for midazolam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral pharmacokinetics (PK) of midazolam after single co-administration with TEV-56286 in healthy volunteers in the fasted state (Part I).</measure>
    <time_frame>Day 3</time_frame>
    <description>PK parameter: AUC(0-inf) for midazolam.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral pharmacokinetics (PK) of midazolam after single co-administration with TEV-56286 in healthy volunteers in the fasted state (Part I).</measure>
    <time_frame>Day 3</time_frame>
    <description>PK parameter: AUC (0-last) for midazolam.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral pharmacokinetics (PK) of caffeine after repeated administration of TEV-56286 in healthy volunteers in the fasted state (Part I).</measure>
    <time_frame>Day 18</time_frame>
    <description>PK parameter: Cmax for caffeine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral pharmacokinetics (PK) of caffeine after repeated administration of TEV-56286 in healthy volunteers in the fasted state (Part I).</measure>
    <time_frame>Day 18</time_frame>
    <description>AUC(0-inf) for caffeine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral pharmacokinetics (PK) of caffeine after repeated administration of TEV-56286 in healthy volunteers in the fasted state (Part I).</measure>
    <time_frame>Day 18</time_frame>
    <description>PK parameter: AUC (0-last) for caffeine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral pharmacokinetics (PK) of midazolam after repeated administration of TEV-56286 in healthy volunteers in the fasted state (Part I).</measure>
    <time_frame>Day 18</time_frame>
    <description>PK parameter: Cmax for midazolam.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral pharmacokinetics (PK) of midazolam after repeated administration of TEV-56286 in healthy volunteers in the fasted state (Part I).</measure>
    <time_frame>Day 18</time_frame>
    <description>PK parameter: AUC(0-inf) for midazolam.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral pharmacokinetics (PK) of midazolam after repeated administration of TEV-56286 in healthy volunteers in the fasted state (Part I).</measure>
    <time_frame>Day 18</time_frame>
    <description>PK parameter: AUC (0-last) for midazolam.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 without fluvoxamine in healthy volunteers after repeated administration in the fasted state (Part II).</measure>
    <time_frame>Day 14</time_frame>
    <description>PK parameter: Cmax for TEV-56286.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 without fluvoxamine in healthy volunteers after repeated administration in the fasted state (Part II).</measure>
    <time_frame>Day 14</time_frame>
    <description>PK parameter: AUC(0-tau) for TEV-56286.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 in healthy volunteers after repeated co-administration with fluvoxamine in the fasted state.</measure>
    <time_frame>Day 19</time_frame>
    <description>PK parameter: Cmax for TEV-56286 (Part II).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 in healthy volunteers after repeated co-administration with fluvoxamine in the fasted state.</measure>
    <time_frame>Day 19</time_frame>
    <description>PK parameter: AUC(0-tau) for TEV-56286 (Part II).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of substrates caffeine and midazolam</measure>
    <time_frame>Day 1, Day 3, Day 18</time_frame>
    <description>PK parameter: Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of substrates caffeine and midazolam</measure>
    <time_frame>Day 1, Day 3, Day 18</time_frame>
    <description>PK parameter: Tlag</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of substrates caffeine and midazolam</measure>
    <time_frame>Day 1, Day 3, Day 18</time_frame>
    <description>PK parameter: lambda-z</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of substrates caffeine and midazolam</measure>
    <time_frame>Day 1, Day 3, Day 18</time_frame>
    <description>PK parameter: T1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of substrates caffeine and midazolam</measure>
    <time_frame>Day 1, Day 3, Day 18</time_frame>
    <description>PK parameter: CL/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of substrates caffeine and midazolam</measure>
    <time_frame>Day 1, Day 3, Day 18</time_frame>
    <description>PK parameter: Vz/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 after repeated co-administration with fluvoxamine</measure>
    <time_frame>Day 19</time_frame>
    <description>PK parameter: Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 after repeated co-administration with fluvoxamine</measure>
    <time_frame>Day 19</time_frame>
    <description>PK parameter: lambda-z</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 after repeated co-administration with fluvoxamine</measure>
    <time_frame>Day 19</time_frame>
    <description>PK parameter: T1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 after repeated co-administration with fluvoxamine</measure>
    <time_frame>Day 19</time_frame>
    <description>PK parameter: CL/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 after repeated co-administration with fluvoxamine</measure>
    <time_frame>Day 19</time_frame>
    <description>PK parameter: Vz/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 as perpetrator drug after co-administration with caffeine and midazolam</measure>
    <time_frame>Day 3</time_frame>
    <description>PK parameter: Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 as perpetrator drug after co-administration with caffeine and midazolam</measure>
    <time_frame>Day 3</time_frame>
    <description>PK parameter: Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 as perpetrator drug after co-administration with caffeine and midazolam</measure>
    <time_frame>Day 3</time_frame>
    <description>PK parameter: AUC (0-last)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286</measure>
    <time_frame>Day 3-18</time_frame>
    <description>PK parameter: Trough concentration for TEV-56286</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 after single co-administration with caffeine and midazolam</measure>
    <time_frame>Day 18</time_frame>
    <description>PK parameter: Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 after single co-administration with caffeine and midazolam</measure>
    <time_frame>Day 18</time_frame>
    <description>PK parameter: Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 after single co-administration with caffeine and midazolam</measure>
    <time_frame>Day 18</time_frame>
    <description>PK parameter: Cmin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 after single co-administration with caffeine and midazolam</measure>
    <time_frame>Day 18</time_frame>
    <description>PK parameter: Cavg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 after single co-administration with caffeine and midazolam</measure>
    <time_frame>Day 18</time_frame>
    <description>PK parameter: AUC (0-tau)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 after single co-administration with caffeine and midazolam</measure>
    <time_frame>Day 18</time_frame>
    <description>PK parameter: AUC (0-last)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of fluvoxamine after repeated co-administration with TEV-56286</measure>
    <time_frame>Day 19</time_frame>
    <description>PK parameter: Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of fluvoxamine after repeated co-administration with TEV-56286</measure>
    <time_frame>Day 19</time_frame>
    <description>PK parameter: Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of fluvoxamine after repeated co-administration with TEV-56286</measure>
    <time_frame>Day 19</time_frame>
    <description>PK parameter: Cmin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of fluvoxamine after repeated co-administration with TEV-56286</measure>
    <time_frame>Day 19</time_frame>
    <description>PK parameter: Cavg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of fluvoxamine after repeated co-administration with TEV-56286</measure>
    <time_frame>Day 19</time_frame>
    <description>PK parameter: AUC (0-tau)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of fluvoxamine after repeated co-administration with TEV-56286</measure>
    <time_frame>Day 19</time_frame>
    <description>PK parameter: AUC (0-last)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of fluvoxamine after repeated co-administration with TEV-56286</measure>
    <time_frame>Day 15-19</time_frame>
    <description>PK parameter: Trough concentration for fluvoxamine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 after first dose administered as part of repeated administration</measure>
    <time_frame>Day 1</time_frame>
    <description>PK parameter: Tlag for TEV-56286</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 following single dose and multiple dose</measure>
    <time_frame>Day 1, Day 14</time_frame>
    <description>PK parameter: Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 following single dose and multiple dose</measure>
    <time_frame>Day 1, Day 14</time_frame>
    <description>PK parameter: Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 following single dose and multiple dose</measure>
    <time_frame>Day 1, Day 14</time_frame>
    <description>PK parameter: AUC (0-tau)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 following single dose and multiple dose</measure>
    <time_frame>Day 1, Day 14</time_frame>
    <description>PK parameter: lambda-z</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 following single dose and multiple dose</measure>
    <time_frame>Day 1, Day 14</time_frame>
    <description>PK parameter: T1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 following single dose and multiple dose</measure>
    <time_frame>Day 1, Day 14</time_frame>
    <description>PK parameter: CL/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 following single dose and multiple dose</measure>
    <time_frame>Day 1, Day 14</time_frame>
    <description>PK parameter: Vz/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 following multiple dose</measure>
    <time_frame>Day 14</time_frame>
    <description>PK parameter: AUC (0-last)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 following multiple dose</measure>
    <time_frame>Day 14</time_frame>
    <description>PK parameter: Cmin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 following multiple dose</measure>
    <time_frame>Day 14</time_frame>
    <description>PK parameter: Cavg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of TEV-56286 following multiple dose</measure>
    <time_frame>Day 14</time_frame>
    <description>PK parameter: Accumulation ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of metabolites paraxanthine and 1-hydroxy midazolam after single administration of caffeine and midazolam</measure>
    <time_frame>Day 1, Day 3, Day 18</time_frame>
    <description>PK parameter: Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of metabolites paraxanthine and 1-hydroxy midazolam after single administration of caffeine and midazolam</measure>
    <time_frame>Day 1, Day 3, Day 18</time_frame>
    <description>PK parameter: Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of metabolites paraxanthine and 1-hydroxy midazolam after single administration of caffeine and midazolam</measure>
    <time_frame>Day 1, Day 3, Day 18</time_frame>
    <description>PK parameter: AUC (0-last)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of metabolites paraxanthine and 1-hydroxy midazolam after single administration of caffeine and midazolam</measure>
    <time_frame>Day 1, Day 3, Day 18</time_frame>
    <description>PK parameter: AUC (0-inf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of metabolites paraxanthine and 1-hydroxy midazolam after single administration of caffeine and midazolam</measure>
    <time_frame>Day 1, Day 3, Day 18</time_frame>
    <description>PK parameter: lambda-z</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of metabolites paraxanthine and 1-hydroxy midazolam after single administration of caffeine and midazolam</measure>
    <time_frame>Day 1, Day 3, Day 18</time_frame>
    <description>PK parameter: T1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetics (PK) of metabolites paraxanthine and 1-hydroxy midazolam after single administration of caffeine and midazolam</measure>
    <time_frame>Day 1, Day 3, Day 18</time_frame>
    <description>PK parameter: parent: metabolite ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events including clinically significant changes in vital signs, ECGs and safety labs</measure>
    <time_frame>Day 1 up to follow up visit (5-11 days post last TEV-56286 dose)</time_frame>
    <description>adverse events and clinically significant changes in vital signs, ECGs and safety labs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants reporting use of concomitant medications</measure>
    <time_frame>Day 1 up to follow up visit (5-11 days post last TEV-56286 dose)</time_frame>
    <description>Number of participants reporting use of concomitant medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Columbia-Suicide Severity Rating Scale (C-SSRS) total score</measure>
    <time_frame>Day 3 to day 21</time_frame>
    <description>Columbia-Suicide Severity Rating Scale (C-SSRS) total score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>anle138b (TEV-56286) as perpetrator (part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: TEV-56286 300 mg QD (single dose and multiple dose for 14 days)&#xD;
Victim drugs:&#xD;
Caffeine 200 mg Midazolam 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>anle138b (TEV-56286) as victim (part II)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: fluvoxamine 100 mg QD for 5 days&#xD;
Victim drug:&#xD;
TEV-56286 150 mg QD for 14 days + 5 days of co-administation with fluvoxamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anle138b (TEV-56286)</intervention_name>
    <description>Anle138b (TEV-56286) as perpetrator</description>
    <arm_group_label>anle138b (TEV-56286) as perpetrator (part I)</arm_group_label>
    <other_name>Caffeine</other_name>
    <other_name>Midazolam</other_name>
    <other_name>Fluvoxamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvoxamine 100 mg QD for 5 days</intervention_name>
    <description>Anle138b (TEV-56286) as victim</description>
    <arm_group_label>anle138b (TEV-56286) as victim (part II)</arm_group_label>
    <other_name>TEV-56286 150 mg QD for 14 days + 5 days of co-administation with fluvoxamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males or healthy females of non-childbearing potential&#xD;
&#xD;
          -  Must provide written informed consent for participation in the study and must be able&#xD;
             to understand the study requirements&#xD;
&#xD;
          -  Body mass index (BMI) 18.5 to 32.0 kg/m2.&#xD;
&#xD;
          -  Must agree to adhere to the contraception requirements defined in the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious adverse reaction or serious hypersensitivity to any drug or formulation&#xD;
             excipients e.g. fluvoxamine, caffeine, midazolam or benzodiazepines or any of its&#xD;
             excipients, or a known drug hypersensitivity idiosyncratic reaction to TEV-56286, or&#xD;
             one of its excipients&#xD;
&#xD;
          -  History of clinically significant cardiovascular, renal, hepatic, dermatological,&#xD;
             chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder,&#xD;
             metabolic diseases or a history of any illness that, in the opinion of the&#xD;
             investigator, might pose additional risk to the subject by participation in the study&#xD;
             or confound the results of the study&#xD;
&#xD;
          -  Acute infection and/or antibiotic treatment within 28 days of Day 1&#xD;
&#xD;
          -  Major trauma or surgery in the 2 months before screening or at any time between&#xD;
             screening and Day 1, or surgery scheduled during the study or follow up period&#xD;
&#xD;
          -  History of malignancy or treatment of malignancy in the last 5 years&#xD;
&#xD;
          -  History of suicidal ideation with an intent and/or plan and behaviour based upon&#xD;
             either clinical history or source documents&#xD;
&#xD;
          -  Personal or family history of arrhythmia, sudden unexplained death at a young age&#xD;
             (before 40 years) in a first-degree relative, or long QT syndrome, or a personal&#xD;
             history of syncope or previous treatment for high blood pressure (BP). Abnormality of&#xD;
             12-lead ECG that may, in the opinion of the investigator, interfere with study&#xD;
             participation&#xD;
&#xD;
          -  Any procedure or disorder that may interfere with drug absorption, distribution,&#xD;
             metabolism, or excretion&#xD;
&#xD;
          -  Clinically significant abnormal clinical chemistry, haematology or urinalysis as&#xD;
             judged by the investigator.&#xD;
&#xD;
          -  Subjects who have received any IMP in a clinical research study within the 90 days&#xD;
             prior to Day 1, or less than 5 elimination half-lives prior to Day 1, whichever is&#xD;
             longer&#xD;
&#xD;
          -  Subjects who are taking, or have taken, any prescribed or over-the-counter drug or&#xD;
             herbal remedies in the 14 days before study medication administration or within 5&#xD;
             half-lives whichever is longer.&#xD;
&#xD;
          -  Subjects who are taking, or have taken hormonal contraceptives (e.g., oral, patch,&#xD;
             injectable or intrauterine device) hormone replacement therapy (HRT) or a long-acting&#xD;
             injectable hormonal within 4 weeks prior to first dose of IMP&#xD;
&#xD;
          -  Subjects who are taking, or have taken any inducer of CYP 1A2, CYP3A4 within 28 days&#xD;
             prior to Day -2&#xD;
&#xD;
          -  History of any drug or alcohol abuse in the past 2 years&#xD;
&#xD;
          -  Current smokers and those who have smoked within the last 12 months or has a positive&#xD;
             urine cotinine test&#xD;
&#xD;
          -  Current users of e-cigarettes and nicotine replacement products and those who have&#xD;
             used these products within the last 12 months&#xD;
&#xD;
          -  Subjects with a previous history of difficulty in swallowing tablets or capsules, or&#xD;
             an anticipated problem with swallowing a large number of capsules&#xD;
&#xD;
          -  Subjects who have consumed grapefruit, grapefruit juice, Seville oranges,&#xD;
             pomelo-containing products, vegetables from the mustard green family (e.g., kale,&#xD;
             broccoli, watercress, collard greens, kohlrabi, brussel sprouts, and mustard) and&#xD;
             charbroiled meats within the 14 days prior to Day -2&#xD;
&#xD;
          -  Subjects who are unwilling to comply with the restricted use of caffeinated beverages&#xD;
             (e.g. coffee, tea, cola) during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nand Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Sciences Mere Way Ruddington Fields Ruddington Nottingham NG11 6JS, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johannes Levin, MD</last_name>
    <phone>+49-6734-9622</phone>
    <phone_ext>8000</phone_ext>
    <email>levin@modag.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Armin Giese, MD</last_name>
    <phone>+49-6734-9622</phone>
    <phone_ext>8000</phone_ext>
    <email>giese@modag.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Quotient Sciences</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nand Singh, BSc, MD, DPM, MFPM</last_name>
      <phone>+44 (0)115 974</phone>
      <phone_ext>9000</phone_ext>
      <email>nand.singh@quotientsciences.com</email>
    </contact>
    <contact_backup>
      <last_name>Sue Melbourne, DipNurs</last_name>
      <phone>+44 (0)115 931</phone>
      <phone_ext>5120</phone_ext>
      <email>sue.melbourne@quotientsciences.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.modag.net</url>
    <description>Description Sponsor Homepage</description>
  </link>
  <reference>
    <citation>Levin J, Sing N, Melbourne S, Morgan A, Mariner C, Spillantini MG, Wegrzynowicz M, Dalley JW, Langer S, Ryazanov S, Leonov A, Griesinger C, Schmidt F, Weckbecker D, Prager K, Matthias T, Giese A. Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial. EBioMedicine. 2022 Jun;80:104021. doi: 10.1016/j.ebiom.2022.104021. Epub 2022 Apr 29.</citation>
    <PMID>35500536</PMID>
  </reference>
  <reference>
    <citation>Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F, Prix C, Pan-Montojo F, Bertsch U, Mitteregger-Kretzschmar G, Geissen M, Eiden M, Leidel F, Hirschberger T, Deeg AA, Krauth JJ, Zinth W, Tavan P, Pilger J, Zweckstetter M, Frank T, Bähr M, Weishaupt JH, Uhr M, Urlaub H, Teichmann U, Samwer M, Bötzel K, Groschup M, Kretzschmar H, Griesinger C, Giese A. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol. 2013 Jun;125(6):795-813. doi: 10.1007/s00401-013-1114-9. Epub 2013 Apr 19.</citation>
    <PMID>23604588</PMID>
  </reference>
  <reference>
    <citation>Drug Interaction Studies M12. ICH Harmonised Guideline. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Draft version endorsed on 24 May 2022.</citation>
  </reference>
  <reference>
    <citation>Clinical Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry. US Food and Drug Administration. 07 Jul 2020. Available online: https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/clinical-drug-interaction-studiescytochrome-p450-enzyme-and-transporter-mediated-drug-interactions (accessed 23 Jun 2022).</citation>
  </reference>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>September 4, 2022</study_first_submitted>
  <study_first_submitted_qc>September 4, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2022</study_first_posted>
  <last_update_submitted>September 13, 2022</last_update_submitted>
  <last_update_submitted_qc>September 13, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anle138b (TEV-56286)</keyword>
  <keyword>alpha-Synuclein</keyword>
  <keyword>Oligomer modulator</keyword>
  <keyword>Multiple System Atrophy</keyword>
  <keyword>Parkinson Disease</keyword>
  <keyword>Alzheimer Disease</keyword>
  <keyword>Neurodegenerative diseases</keyword>
  <keyword>Tauopathies</keyword>
  <keyword>Amyloid</keyword>
  <keyword>Drug-drug interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Fluvoxamine</mesh_term>
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

